UA75565C2 - Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням - Google Patents

Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням Download PDF

Info

Publication number: UA75565C2
Authority: UA; Ukraine
Prior art keywords: protein; angiogenesis; item; tissue; pharmaceutical compound
Prior art date: 1998-05-29

Application number

UA2000127086A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Дейвід Е. Череш

Брайен Елісейрі

Памела Л. Шварцберг

Original Assignee

Scripps Research Inst

Us Government

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-29

Filing date

1999-05-28

Publication date

2006-05-15

1999-05-28 Application filed by Scripps Research Inst, Us Government filed Critical Scripps Research Inst

2006-05-15 Publication of UA75565C2 publication Critical patent/UA75565C2/uk

Links

230000033115 angiogenesis Effects 0.000 title claims abstract description 129
238000000034 method Methods 0.000 title claims abstract description 85
150000001875 compounds Chemical class 0.000 title claims abstract description 60
230000014399 negative regulation of angiogenesis Effects 0.000 title claims abstract description 18
230000026341 positive regulation of angiogenesis Effects 0.000 title claims abstract description 5
108090000623 proteins and genes Proteins 0.000 claims abstract description 138
102000004169 proteins and genes Human genes 0.000 claims abstract description 101
230000000694 effects Effects 0.000 claims abstract description 37
239000013604 expression vector Substances 0.000 claims abstract description 25
230000003612 virological effect Effects 0.000 claims abstract description 20
108091000080 Phosphotransferase Proteins 0.000 claims abstract description 16
102000020233 phosphotransferase Human genes 0.000 claims abstract description 16
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 10
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 10
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 8
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 8
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 5
108020004705 Codon Proteins 0.000 claims abstract description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 5
239000004473 Threonine Substances 0.000 claims abstract description 5
206010028980 Neoplasm Diseases 0.000 claims description 92
150000007523 nucleic acids Chemical class 0.000 claims description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
201000010099 disease Diseases 0.000 claims description 33
102000039446 nucleic acids Human genes 0.000 claims description 33
108020004707 nucleic acids Proteins 0.000 claims description 33
125000000539 amino acid group Chemical group 0.000 claims description 28
230000001225 therapeutic effect Effects 0.000 claims description 21
230000002401 inhibitory effect Effects 0.000 claims description 18
230000001177 retroviral effect Effects 0.000 claims description 18
206010027476 Metastases Diseases 0.000 claims description 11
239000002502 liposome Substances 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
208000037803 restenosis Diseases 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 6
230000004936 stimulating effect Effects 0.000 claims description 6
206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
230000002207 retinal effect Effects 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 3
238000007912 intraperitoneal administration Methods 0.000 claims description 3
208000002780 macular degeneration Diseases 0.000 claims description 3
239000004033 plastic Substances 0.000 claims description 3
229920003023 plastic Polymers 0.000 claims description 3
238000007631 vascular surgery Methods 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 2
208000017442 Retinal disease Diseases 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
208000035719 Maculopathy Diseases 0.000 claims 1
206010038923 Retinopathy Diseases 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
238000007918 intramuscular administration Methods 0.000 claims 1
150000001413 amino acids Chemical class 0.000 abstract description 11
210000001519 tissue Anatomy 0.000 description 101
235000018102 proteins Nutrition 0.000 description 86
239000013598 vector Substances 0.000 description 79
230000014509 gene expression Effects 0.000 description 49
102000053602 DNA Human genes 0.000 description 43
210000004027 cell Anatomy 0.000 description 43
108020004414 DNA Proteins 0.000 description 40
238000001415 gene therapy Methods 0.000 description 27
206010044696 Tropical spastic paresis Diseases 0.000 description 26
210000004204 blood vessel Anatomy 0.000 description 26
230000012010 growth Effects 0.000 description 23
108090000765 processed proteins & peptides Proteins 0.000 description 22
238000011282 treatment Methods 0.000 description 22
239000002299 complementary DNA Substances 0.000 description 21
206010029113 Neovascularisation Diseases 0.000 description 20
241000700605 Viruses Species 0.000 description 19
230000035772 mutation Effects 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 17
238000012546 transfer Methods 0.000 description 17
241001430294 unidentified retrovirus Species 0.000 description 17
241000287828 Gallus gallus Species 0.000 description 16
235000013330 chicken meat Nutrition 0.000 description 16
239000012634 fragment Substances 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 16
239000003102 growth factor Substances 0.000 description 15
239000002773 nucleotide Substances 0.000 description 15
125000003729 nucleotide group Chemical group 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
241000701161 unidentified adenovirus Species 0.000 description 15
108020004511 Recombinant DNA Proteins 0.000 description 14
230000008569 process Effects 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
230000004614 tumor growth Effects 0.000 description 13
210000004087 cornea Anatomy 0.000 description 11
230000002491 angiogenic effect Effects 0.000 description 10
230000002792 vascular Effects 0.000 description 10
239000013603 viral vector Substances 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
238000010367 cloning Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
208000000172 Medulloblastoma Diseases 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
210000003837 chick embryo Anatomy 0.000 description 8
239000008177 pharmaceutical agent Substances 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000003556 assay Methods 0.000 description 7
238000010276 construction Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000000670 limiting effect Effects 0.000 description 7
239000005022 packaging material Substances 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
241000271566 Aves Species 0.000 description 6
101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 6
101001030069 Homo sapiens Major vault protein Proteins 0.000 description 6
101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 6
101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
239000000284 extract Substances 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
230000010076 replication Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
241000700584 Simplexvirus Species 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
238000001476 gene delivery Methods 0.000 description 5
239000005090 green fluorescent protein Substances 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
210000001161 mammalian embryo Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
210000005167 vascular cell Anatomy 0.000 description 5
239000013607 AAV vector Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
241000714177 Murine leukemia virus Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
108700005077 Viral Genes Proteins 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
229940121369 angiogenesis inhibitor Drugs 0.000 description 4
239000004037 angiogenesis inhibitor Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
210000003711 chorioallantoic membrane Anatomy 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000013020 embryo development Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
-1 for example Substances 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000713842 Avian sarcoma virus Species 0.000 description 3
241000283707 Capra Species 0.000 description 3
102000001189 Cyclic Peptides Human genes 0.000 description 3
108010069514 Cyclic Peptides Proteins 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000004087 circulation Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
210000003953 foreskin Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
230000035876 healing Effects 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000000021 kinase assay Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000013615 primer Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
241000894007 species Species 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
102000002281 Adenylate kinase Human genes 0.000 description 2
108020000543 Adenylate kinase Proteins 0.000 description 2
208000003120 Angiofibroma Diseases 0.000 description 2
241000713826 Avian leukosis virus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
241000713800 Feline immunodeficiency virus Species 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
102100022337 Integrin alpha-V Human genes 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000052812 Ornithine decarboxylases Human genes 0.000 description 2
108700005126 Ornithine decarboxylases Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108010048673 Vitronectin Receptors Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000004712 air sac Anatomy 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
230000009285 allergic inflammation Effects 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
229960003290 cortisone acetate Drugs 0.000 description 2
238000002316 cosmetic surgery Methods 0.000 description 2
230000002338 cryopreservative effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
210000001650 focal adhesion Anatomy 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
102000045360 human SDHB Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000003142 neovascular glaucoma Diseases 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000000123 paper Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000002271 resection Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
208000017572 squamous cell neoplasm Diseases 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000008467 tissue growth Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
230000004862 vasculogenesis Effects 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
241000702423 Adeno-associated virus - 2 Species 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
229940122097 Collagenase inhibitor Drugs 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
108091006067 Goα proteins Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 description 1
101000633751 Homo sapiens High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
101000689365 Homo sapiens Pyridoxal phosphate homeostasis protein Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000713673 Human foamy virus Species 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
241001562081 Ikeda Species 0.000 description 1
101150004367 Il4i1 gene Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
102100029698 Metallothionein-1A Human genes 0.000 description 1
101710196500 Metallothionein-1A Proteins 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
101100072790 Mus musculus Irf4 gene Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004211 Platelet factor 4 Human genes 0.000 description 1
108090000778 Platelet factor 4 Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
102100024487 Pyridoxal phosphate homeostasis protein Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000009378 breast hemangioma Diseases 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
DIOLOCSXUMYFJN-UHFFFAOYSA-N calcium;azane Chemical compound N.[Ca+2] DIOLOCSXUMYFJN-UHFFFAOYSA-N 0.000 description 1
238000005266 casting Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004182 chemical digestion Methods 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000002442 collagenase inhibitor Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000021953 cytokinesis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000009762 endothelial cell differentiation Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000007667 floating Methods 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
239000011888 foil Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000003517 fume Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
235000014413 iron hydroxide Nutrition 0.000 description 1
NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
230000030716 positive regulation of phosphorylation Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
244000144977 poultry Species 0.000 description 1
235000013594 poultry meat Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
210000000998 shell membrane Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
108010036901 thymidine kinase 1 Proteins 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000009790 vascular invasion Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Microbiology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)

UA2000127086A 1998-05-29 1999-05-28 Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням UA75565C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8722098P	1998-05-29	1998-05-29
PCT/US1999/011780 WO1999061590A1 (en)	1998-05-29	1999-05-28	Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src

Publications (1)

Publication Number	Publication Date
UA75565C2 true UA75565C2 (uk)	2006-05-15

Family

ID=22203825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000127086A UA75565C2 (uk)	1998-05-29	1999-05-28	Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням

Country Status (23)

Country	Link
US (1)	US7585841B2 (de)
EP (1)	EP1082415B1 (de)
JP (1)	JP4806487B2 (de)
KR (1)	KR20010085261A (de)
CN (1)	CN1304567C (de)
AT (1)	ATE506073T1 (de)
AU (1)	AU762955C (de)
BR (1)	BR9910787A (de)
CA (1)	CA2330025C (de)
CZ (1)	CZ302918B6 (de)
DE (1)	DE69943374D1 (de)
DK (1)	DK1082415T3 (de)
ES (1)	ES2361659T3 (de)
HU (1)	HU227985B1 (de)
MX (1)	MXPA00011821A (de)
NO (1)	NO327610B1 (de)
PT (1)	PT1082415E (de)
RU (1)	RU2222342C2 (de)
SK (1)	SK287330B6 (de)
TR (1)	TR200100430T2 (de)
UA (1)	UA75565C2 (de)
WO (1)	WO1999061590A1 (de)
ZA (1)	ZA200007321B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA00011821A (es) *	1998-05-29	2004-07-30	Scripps Research Inst	Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
US20030130209A1 (en) *	1999-12-22	2003-07-10	Cheresh David A.	Method of treatment of myocardial infarction
US6685938B1 (en) *	1998-05-29	2004-02-03	The Scripps Research Institute	Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6297258B1 (en) *	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
EP1250155B1 (de) *	1999-12-22	2008-04-16	The Scripps Research Institute	Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
US7485414B2 (en)	2002-08-30	2009-02-03	Rigel Pharmaceuticals, Inc.	Modulators of angiogenesis
US20080280987A1 (en) *	2006-08-31	2008-11-13	Desai Neil P	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008054792A2 (en) *	2006-10-31	2008-05-08	University Of Toledo	Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases
DE102007037008B4 (de) *	2007-08-06	2015-09-10	Siemens Aktiengesellschaft	Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
WO2010105172A1 (en)	2009-03-13	2010-09-16	Abraxis Bioscience, Llc	Combination therapy with thiocolchicine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264618A (en) *	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
AU7432496A (en) *	1995-10-13	1998-05-11	Regents Of The University Of Minnesota	Consolidated ligands with increased affinities and methods of use thereof
US6335010B1 (en) *	1996-11-08	2002-01-01	University Of California At San Diego	Gene therapy in coronary angioplasty and bypass
MXPA00011821A (es) *	1998-05-29	2004-07-30	Scripps Research Inst	Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
GB2341182A (en) *	1998-09-01	2000-03-08	Yamanouchi Uk Ltd	Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity

1999
- 1999-05-28 MX MXPA00011821A patent/MXPA00011821A/es not_active IP Right Cessation
- 1999-05-28 CA CA002330025A patent/CA2330025C/en not_active Expired - Fee Related
- 1999-05-28 ES ES99924535T patent/ES2361659T3/es not_active Expired - Lifetime
- 1999-05-28 DE DE69943374T patent/DE69943374D1/de not_active Expired - Lifetime
- 1999-05-28 KR KR1020007013490A patent/KR20010085261A/ko not_active Ceased
- 1999-05-28 AU AU41013/99A patent/AU762955C/en not_active Ceased
- 1999-05-28 AT AT99924535T patent/ATE506073T1/de active
- 1999-05-28 HU HU0102614A patent/HU227985B1/hu not_active IP Right Cessation
- 1999-05-28 WO PCT/US1999/011780 patent/WO1999061590A1/en not_active Ceased
- 1999-05-28 EP EP99924535A patent/EP1082415B1/de not_active Expired - Lifetime
- 1999-05-28 TR TR2001/00430T patent/TR200100430T2/xx unknown
- 1999-05-28 BR BR9910787-2A patent/BR9910787A/pt not_active IP Right Cessation
- 1999-05-28 CN CNB998090735A patent/CN1304567C/zh not_active Expired - Fee Related
- 1999-05-28 DK DK99924535.0T patent/DK1082415T3/da active
- 1999-05-28 RU RU2000133327/15A patent/RU2222342C2/ru not_active IP Right Cessation
- 1999-05-28 PT PT99924535T patent/PT1082415E/pt unknown
- 1999-05-28 SK SK1811-2000A patent/SK287330B6/sk not_active IP Right Cessation
- 1999-05-28 JP JP2000550976A patent/JP4806487B2/ja not_active Expired - Fee Related
- 1999-05-28 CZ CZ20004435A patent/CZ302918B6/cs not_active IP Right Cessation
- 1999-05-28 UA UA2000127086A patent/UA75565C2/uk unknown
2000
- 2000-11-28 NO NO20006026A patent/NO327610B1/no not_active IP Right Cessation
- 2000-12-08 ZA ZA200007321A patent/ZA200007321B/xx unknown
2005
- 2005-09-19 US US11/230,995 patent/US7585841B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2330025A1 (en)	1999-12-02
CA2330025C (en)	2009-03-17
EP1082415A4 (de)	2003-07-09
ZA200007321B (en)	2002-03-08
SK18112000A3 (sk)	2001-09-11
EP1082415A1 (de)	2001-03-14
AU762955C (en)	2005-03-24
NO327610B1 (no)	2009-08-31
HK1041289A1 (en)	2002-07-05
SK287330B6 (sk)	2010-07-07
WO1999061590A1 (en)	1999-12-02
US7585841B2 (en)	2009-09-08
US20060009412A1 (en)	2006-01-12
HUP0102614A2 (hu)	2001-11-28
JP4806487B2 (ja)	2011-11-02
PT1082415E (pt)	2011-07-04
DK1082415T3 (da)	2011-06-14
MXPA00011821A (es)	2004-07-30
WO1999061590A9 (en)	2000-03-09
CZ302918B6 (cs)	2012-01-18
ATE506073T1 (de)	2011-05-15
ES2361659T3 (es)	2011-06-21
KR20010085261A (ko)	2001-09-07
BR9910787A (pt)	2001-10-30
HU227985B1 (en)	2012-07-30
NO20006026L (no)	2001-01-24
CN1304567C (zh)	2007-03-14
JP2002516344A (ja)	2002-06-04
RU2222342C2 (ru)	2004-01-27
TR200100430T2 (tr)	2002-05-21
AU4101399A (en)	1999-12-13
EP1082415B1 (de)	2011-04-20
CZ20004435A3 (en)	2001-06-13
NO20006026D0 (no)	2000-11-28
HUP0102614A3 (en)	2005-11-28
DE69943374D1 (de)	2011-06-01
AU762955B2 (en)	2003-07-10
CN1319131A (zh)	2001-10-24

Publication	Publication Date	Title
ES2936474T3 (es)	2023-03-17	Construcción del receptor de antígeno quimérico dirigido al antígeno cd20 y actividad identificación de las células T modificadas del mismo
AU781444B2 (en)	2005-05-26	Angiogenesis and vascular permeability modulators and inhibitors
US20060148742A1 (en)	2006-07-06	Polynucleotide delivery to cardiac tissue
UA75565C2 (uk)	2006-05-15	Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням
RU2257911C2 (ru)	2005-08-10	Способы и композиции, применимые для модуляции ангиогенеза с использованием протеинкиназы raf и ras
JPH09505557A (ja)	1997-06-03	ヒト腫瘍細胞の遺伝子形質転換によるヒト腫瘍の治療
US11560412B2 (en)	2023-01-24	Compositions comprising GRIM-19 therapeutics and methods of use
ES2297479T3 (es)	2008-05-01	Infiltracion aumentada en tumor de celulas t por el mutante ligth.
EP4106875A1 (de)	2022-12-28	Gentherapie
KR20070060721A (ko)	2007-06-13	히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물
WO2001007605A1 (en)	2001-02-01	Immunosuppression by cell surface expression of recombinant cd154
MXPA02006207A (en)	2003-11-07	Angiogenesis and vascular permeability modulators and inhibitors
ZA200201761B (en)	2003-06-02	Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras.